Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses-Reference-Cited by-同舟云学术

Boronic Acid Transition State Inhibitors as Potent Inactivators of KPC and CTX-M β-Lactamases: Biochemical and Structural Analyses

Published:2023-01-24 Issue:1 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Alsenani Tahani A.¹,Rodríguez María Margarita²³,Ghiglione Barbara²³,Taracila Magdalena A.⁴⁵,Mojica Maria F.⁵⁶⁷,Rojas Laura J.⁵⁶⁷,Hujer Andrea M.⁴⁵,Gutkind Gabriel²³^ORCID,Bethel Christopher R.⁵,Rather Philip N.⁸⁹¹⁰,Introvigne Maria Luisa¹¹,Prati Fabio¹¹,Caselli Emilia¹¹,Power Pablo²³^ORCID,van den Akker Focco¹,Bonomo Robert A.¹⁴⁵⁶⁷^ORCID

Affiliation:

1. Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

2. Universidad de Buenos Aires, Facultad de Farmacia y Bioquimica, Instituto de Investigaciones en Bacteriologia y Virologia Molecular, Buenos Aires, Argentina

3. Consejo Nacional de Investigaciones Científicas y Tecnicas, Buenos Aires, Argentina

4. Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

5. Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA

6. Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

7. CWRU—Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology, Cleveland, Ohio, USA

8. Department of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA

9. Emory Antibiotic Resistance Center, Emory University, Atlanta, Georgia, USA

10. Research Service, Atlanta VA Medical Center, Decatur, Georgia, USA

11. Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy

Abstract

Design of novel β-lactamase inhibitors (BLIs) is one of the currently accepted strategies to combat the threat of cephalosporin and carbapenem resistance in Gram-negative bacteria. B oronic a cid t ransition s tate i nhibitors (BATSIs) are competitive, reversible BLIs that offer promise as novel therapeutic agents. In this study, the activities of two α-amido-β-triazolylethaneboronic acid transition state inhibitors (S02030 and MB_076) targeting representative KPC (KPC-2) and CTX-M (CTX-M-96, a CTX-M-15-type extended-spectrum β-lactamase [ESBL]) β-lactamases were evaluated.

Funder

University of Buenos Aires

Harrington Foundation

U.S. Department of Veterans Affairs

U.S. Department of Veterans Affairs (VA) Grants

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00930-22

Reference25 articles.